pomalidomide peg2 tos

Pomalidomide-PEG2-Tos is a compound that consists of an E3 ligase ligand-linker conjugate. It is composed of a cereblon ligand conjugated to a two-unit PEG linker[1].

Pomalidomide-PEG2-OH enables the synthesis of molecules for targeted protein degradation and PROTAC (proteolysis-targeting chimeras) technology.

Pomalidomide-PEG2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based CRBN ligand and linker used in PROTAC technology.

(S,R,S)-AHPC-(C3- PEG) 2- C6- Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker. (S,R,S)-AHPC-(C3- PEG) 2- C6- Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays[1].

DBCO-(PEG2-VC-PAB-MMAE)2 consists of Monomethyl auristatin E (MMAE), a toxin payload in antibody-drug conjugate [1], conjugated to the cleavable linker DBCO-(PEG2-VC-PAB)2. MMAE, a potent tubulin inhibitor, serves as the cytotoxic component in this formulation.

Tos-PEG2-Boc is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

2-(Azido-PEG2-amido)-13-propandiol is a Polyethylene glycol (PEG)-based PROTAC linker used for the synthesis of PROTACs[1].

Pomalidomide-C2-amido-(C1-O-C5-O-C1)2-COOH is a chemically synthesized compound, designed as an E3 ligase ligand-linker conjugate, integrating the cereblon ligand derived from Pomalidomide and a linker employed in PROTAC technology. This compound serves to facilitate targeted protein degradation through the modulation of E3 ligase activity, enabling the selective elimination of specific proteins of interest.

m-PEG2-Tos is a uncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 is a synthesized conjugate compound known as an E3 ligase ligand-linker. It incorporates a cereblon ligand based on Thalidomide and a 3-unit PEG linker. This compound is specifically designed for use in PROTAC technology applications.

Pomalidomide 4'-PEG2-azide is a synthetic E3 ligase ligand-linker conjugate containing a Pomalidomide-based cereblon ligand and a linker.

Pomalidomide-amido-C4-amido-PEG2-C2-NH-Boc is a novel synthesized conjugate compound functioning as an E3 ligase ligand-linker in PROTAC technology. This compound incorporates a Pomalidomide-derived cereblon ligand, which binds selectively to the E3 ligase cereblon, and a 2-unit PEG linker, which provides stability and flexibility to the conjugate.

Pomalidomide-PEG2-CO2H is a synthetic E3 ligase ligand-linker conjugate containing a Pomalidomide-based cereblon ligand and a 2-unit PEG linker.

m-PEG-Tos (MW 2000) is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Pomalidomide-PEG2-azide is a synthetic conjugate consisting of a cereblon ligand derived from Pomalidomide and a 2-unit PEG linker, designed for use in PROTAC technology as a ligand-linker conjugate of E3 ligase.

Bis-Tos-(2-hydroxyethyl disulfide) is a cleavable linker employed in the synthesis of antibody-drug conjugates (ADCs)[1].

Tos-PEG2-C2-Boc is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

DBCO-(PEG2-Val-Cit-PAB)2 is a dual cleavable ADC linker for antibody-drug conjugates (ADCs).

Tos-PEG2-CH2-Boc is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Benzyl-PEG2-Tos is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Propargyl-PEG2-Tos is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

(2-Pyridyldithio)-PEG2-Boc is a polyethylene glycol-based PROTAC linker utilized for the synthesis of PROTACs[1].

Tos-PEG2-CH2COOH is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Tos-PEG2-OH is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Tos-PEG2-NH-Boc is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Tos-PEG2-O-Propargyl is a polyethylene glycol (PEG)-based proteolysis targeting chimera (PROTAC) linker, commonly employed for the synthesis of Thalidomide-O-PEG2-propargyl[1].

Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 is a synthetic conjugate compound that combines a Thalidomide-based cereblon ligand and a linker, which is commonly utilized in PROTAC technology. This compound acts as a connector between the target protein and the E3 ligase, facilitating targeted protein degradation.

DSPE-PEG-2-Aminoethyl-alpha-mannopyranoside (MW 2000) is a polyethylene glycol (PEG) derived linker. This specific linker is utilized in the synthesis of PROTACs, or proteolysis targeting chimeras [1].

Hydroxy-PEG2-(CH2)2-Boc is a uncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Tos-PEG2-NH2 (PROTAC Linker 27) is a Polyethylene Glycol (PEG)-based linker used for the synthesis of Proteolysis-Targeting Chimeras (PROTACs)[1].